BK Viremia; BKV DNAemia

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Memo Therapeutics
Memo TherapeuticsSwitzerland - Schlieren
1 program
1
Anti-BK polyomavirusPhase 2/31 trial
Active Trials
NCT05769582Completed95Est. Jul 2025

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
Memo TherapeuticsAnti-BK polyomavirus

Clinical Trials (1)

Total enrollment: 95 patients across 1 trials

NCT05769582Memo TherapeuticsAnti-BK polyomavirus

Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

Start: Apr 2023Est. completion: Jul 202595 patients
Phase 2/3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space